This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. MRKR, LPCN, COCP, CING, GELS, LEXX, BFRG, PMN, GOVX, and PRPHShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Marker Therapeutics (MRKR), Lipocine (LPCN), Cocrystal Pharma (COCP), Cingulate (CING), Gelteq (GELS), Lexaria Bioscience (LEXX), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), GeoVax Labs (GOVX), and ProPhase Labs (PRPH). These companies are all part of the "medical" sector. Novus Therapeutics vs. Its Competitors Marker Therapeutics Lipocine Cocrystal Pharma Cingulate Gelteq Lexaria Bioscience Bullfrog AI ProMIS Neurosciences GeoVax Labs ProPhase Labs Marker Therapeutics (NASDAQ:MRKR) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends. Which has better earnings and valuation, MRKR or NVUS? Marker Therapeutics has higher revenue and earnings than Novus Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$6.59M2.75-$8.24M-$1.33-1.20Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.13 Which has more risk and volatility, MRKR or NVUS? Marker Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Does the media refer more to MRKR or NVUS? In the previous week, Marker Therapeutics had 2 more articles in the media than Novus Therapeutics. MarketBeat recorded 2 mentions for Marker Therapeutics and 0 mentions for Novus Therapeutics. Marker Therapeutics' average media sentiment score of 0.93 beat Novus Therapeutics' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Marker Therapeutics Positive Novus Therapeutics Neutral Is MRKR or NVUS more profitable? Novus Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% Novus Therapeutics N/A -133.49%-30.52% Does the MarketBeat Community prefer MRKR or NVUS? Novus Therapeutics received 177 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 66.84% of users gave Novus Therapeutics an outperform vote while only 64.66% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7564.66% Underperform Votes4135.34% Novus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% Do analysts rate MRKR or NVUS? Marker Therapeutics currently has a consensus price target of $13.17, indicating a potential upside of 722.92%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in MRKR or NVUS? 22.4% of Marker Therapeutics shares are held by institutional investors. 14.5% of Marker Therapeutics shares are held by company insiders. Comparatively, 2.2% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryMarker Therapeutics beats Novus Therapeutics on 12 of the 18 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.12M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.16%P/E Ratio-0.138.5026.7819.65Price / SalesN/A263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book0.226.526.964.59Net Income-$16.01M$143.48M$3.23B$248.23M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$2.87-4.3%N/A+2.0%$4.12MN/A-0.137High Trading VolumeMRKRMarker Therapeutics4.269 of 5 stars$1.52+7.8%$13.17+766.2%-60.2%$17.20M$6.59M-1.1460Positive NewsLPCNLipocine2.1535 of 5 stars$3.20-2.4%$9.00+181.3%-61.7%$17.12M$3.67M-4.2110News CoverageAnalyst ForecastAnalyst RevisionGap DownCOCPCocrystal Pharma2.6139 of 5 stars$1.68+1.8%$7.00+316.7%-41.0%$17.09MN/A-0.9110Short Interest ↑CINGCingulate2.0998 of 5 stars$3.98flat$26.00+553.3%+506.1%$16.90MN/A-0.4720Short Interest ↑GELSGelteqN/A$1.79+19.3%N/AN/A$16.89MN/A0.00N/APositive NewsGap DownLEXXLexaria Bioscience2.5112 of 5 stars$0.92-5.7%$7.00+659.9%-70.3%$16.18M$525.92K-1.847News CoveragePositive NewsGap DownBFRGBullfrog AI1.4697 of 5 stars$1.71flatN/A-37.4%$16.10M$60K-2.014News CoveragePositive NewsPMNProMIS Neurosciences2.3232 of 5 stars$0.49-2.0%$4.50+818.4%-68.5%$16.02MN/A-4.905Positive NewsGOVXGeoVax Labs3.3818 of 5 stars$1.05+1.0%$11.10+957.1%-26.4%$15.95M$5.59M-0.2910News CoveragePRPHProPhase Labs1.2668 of 5 stars$0.38+1.9%N/A-92.9%$15.82M$5.85M-0.30130Short Interest ↑Gap Down Related Companies and Tools Related Companies MRKR Alternatives LPCN Alternatives COCP Alternatives CING Alternatives GELS Alternatives LEXX Alternatives BFRG Alternatives PMN Alternatives GOVX Alternatives PRPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
